Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Assets Average (2020 - 2025)

Keros Therapeutics filings provide 6 years of Assets Average readings, the most recent being $540.4 million for Q4 2025.

  • On a quarterly basis, Assets Average fell 9.57% to $540.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $540.4 million, a 9.57% decrease, with the full-year FY2025 number at $477.0 million, down 3.25% from a year prior.
  • Assets Average hit $540.4 million in Q4 2025 for Keros Therapeutics, down from $750.0 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $770.9 million in Q2 2025 to a low of $230.9 million in Q2 2022.
  • Median Assets Average over the past 5 years was $346.9 million (2023), compared with a mean of $408.4 million.
  • Biggest five-year swings in Assets Average: surged 636.82% in 2021 and later decreased 9.57% in 2025.
  • Keros Therapeutics' Assets Average stood at $242.6 million in 2021, then increased by 15.28% to $279.7 million in 2022, then increased by 24.48% to $348.1 million in 2023, then soared by 71.65% to $597.6 million in 2024, then fell by 9.57% to $540.4 million in 2025.
  • The last three reported values for Assets Average were $540.4 million (Q4 2025), $750.0 million (Q3 2025), and $770.9 million (Q2 2025) per Business Quant data.